320 related articles for article (PubMed ID: 31704279)
21. Opportunistic infections complicating immunotherapy for non-small cell lung cancer.
Liu Z; Liu T; Zhang X; Si X; Wang H; Zhang J; Huang H; Sun X; Wang J; Wang M; Zhang L
Thorac Cancer; 2020 Jun; 11(6):1689-1694. PubMed ID: 32311221
[TBL] [Abstract][Full Text] [Related]
22. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
23. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].
Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J
Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489
[TBL] [Abstract][Full Text] [Related]
24. Aggravation of depigmentation for a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: case report.
Xu Y; Cai Y; Zu J; Wang X; Wang Y; Sun C; Guo Y; Shao G; Yang Z; Qiu S; Ma K
Immunotherapy; 2020 Feb; 12(3):175-181. PubMed ID: 32064977
[TBL] [Abstract][Full Text] [Related]
25. Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of Thymoma.
Lara MS; Afify A; Ellis MP; Phan CT; Richman DP; Riess JW
Clin Lung Cancer; 2019 Jul; 20(4):e489-e491. PubMed ID: 31085042
[No Abstract] [Full Text] [Related]
26. Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report.
Utsumi H; Araya J; Okuda K; Watanabe J; Takekoshi D; Fujita Y; Hashimoto M; Wakui H; Minagawa S; Numata T; Hara H; Kuwano K
Cancer Immunol Immunother; 2020 Oct; 69(10):2033-2039. PubMed ID: 32415507
[TBL] [Abstract][Full Text] [Related]
27. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
[TBL] [Abstract][Full Text] [Related]
28. Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab.
Kogure Y; Ishii Y; Oki M
J Thorac Oncol; 2019 Mar; 14(3):e55-e57. PubMed ID: 30782385
[No Abstract] [Full Text] [Related]
29. Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy.
Okeya K; Kawagishi Y; Muranaka E; Izumida T; Tsuji H; Takeda S
Intern Med; 2019 Nov; 58(22):3295-3298. PubMed ID: 31327828
[TBL] [Abstract][Full Text] [Related]
30. Successful Retreatment Using Pembrolizumab for Non-small-cell Lung Cancer After Severe Immune-related Hepatitis: A Case Report.
Kobayashi K; Nakachi I; Mitsuishi A; Arai D; Sakurai K; Masaki K; Chiyotani A; Takahashi H; Tahara T; Soejima K
Clin Lung Cancer; 2020 Jan; 21(1):e30-e32. PubMed ID: 31699508
[No Abstract] [Full Text] [Related]
31. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
32. Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer.
Bosch-Barrera J; Oliva E; Sais E; Vásquez CA; Roselló A; Menéndez JA
Anticancer Drugs; 2019 Nov; 30(10):1067-1070. PubMed ID: 31567311
[TBL] [Abstract][Full Text] [Related]
33. Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis.
Chen Y; Hu J; Bu F; Zhang H; Fei K; Zhang P
BMC Cancer; 2020 Jul; 20(1):707. PubMed ID: 32727409
[TBL] [Abstract][Full Text] [Related]
34. Pulmonary complications of tyrosine kinase inhibitors and immune checkpoint inhibitors in patients with non-small cell lung cancer.
Gupta K; Uchel T; Karamian G; Loschner A
Cancer Treat Res Commun; 2021; 28():100439. PubMed ID: 34333246
[TBL] [Abstract][Full Text] [Related]
35. The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients.
Zhai X; Zhang J; Tian Y; Li J; Jing W; Guo H; Zhu H
Cancer Biol Med; 2020 Aug; 17(3):599-611. PubMed ID: 32944393
[TBL] [Abstract][Full Text] [Related]
36. Anlotinib succeeded in rescue therapy for hyperprogression induced by immune checkpoint inhibitors: a case report.
Chen L; Liu D; Zhang Y; Jia Y; Zhao X; Liu M; Kong T
Immunotherapy; 2023 Jun; 15(9):631-639. PubMed ID: 37020412
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan.
Hsu JC; Lin JY; Hsu MY; Lin PC
PLoS One; 2018; 13(8):e0202725. PubMed ID: 30142174
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
39. Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer.
Bar J; Ofek E; Barshack I; Gottfried T; Zadok O; Kamer I; Urban D; Perelman M; Onn A
Lung Cancer; 2019 Dec; 138():109-115. PubMed ID: 31683093
[TBL] [Abstract][Full Text] [Related]
40. Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.
Cosimati A; Rossi L; Didona D; Forcella C; Didona B
J Oncol Pharm Pract; 2021 Apr; 27(3):727-733. PubMed ID: 32772795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
